Custopharm, Inc. v. Fresenius Kabi USA, LLC
6:21-cv-00148
Overview
Parties
Defendant
Fresenius Kabi USA, LLC Operating Company
Represented By
2 Attorneys ListedConnor Lee & Shumaker PLLC
609 Castle Ridge Road, Suite 450
Plaintiff
Custopharm, Inc. Operating Company
Represented By
3 Attorneys ListedHahn, Loeser & Parks, LLP
200 West Madison Street, Suite 2700, Chicago, IL 60606
Hahn, Loeser & Parks, LLP
200 West Madison Street, Suite 2700, Chicago, IL 60606
McGinnis, Lochridge LLP
1111 W. 6th Street, Suite 400, Austin, TX 78703
Court & Judges
Court
District Court, W.D. Texas (txwd)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 8 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| π¨π¦ Canada | Canada Counterpart | View Official Patent → | |
| π PCT International (WIPO) | PCT World Application | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US9782376
Levothyroxine liquid formulations
|
Filed: 2016-12-01
Issued: 2017-10-10
|
Active (10.0 yrs remaining)
Expires: 2036-12-01
|
|
|
US10398669
Levothyroxine liquid formulations
|
Filed: 2017-09-11
Issued: 2019-09-03
|
Active (10.8 yrs remaining)
Expires: 2037-09-11
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term; injunctive relief viable.
Standard Statutory Term β No obviousness-type double patenting noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).